Browse News
Filter News
Found 20 articles
-
Hyundai Bioscience announces that "Xafty is the only antiviral that can be immediately used for the treatment of Dengue fever"
10/13/2023
Hyundai Bioscience announced that Xafty™, a broad-spectrum antiviral drug, can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection".
-
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
5/3/2023
Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty'.
-
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
11/25/2022
Hyundai Bioscience announced on November 24th, 2022, that it is collaborating with an Australian cancer hospital for its global Phase 1 clinical trial on pancreatic cancer with Polytaxel, which was developed as so-called 'pain-free' anticancer drug, based on a novel inorganic polymer nanohybrid drug delivery platform technology.
-
Bavarian Nordic announced the U.S. Biomedical Advanced Research and Development Authority has ordered an additional 500,000 doses of its monkeypox vaccine, Jynneos.
-
Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease's origin. Here are the latest updates on the monkeypox virus.
-
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA
5/26/2022
Hyundai Bioscience will go straight to the US with its broad-spectrum antiviral drug candidate to treat monkeypox.
-
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
-
A novel universal antiviral drug introduced in Korea
5/12/2022
Hyundai Bioscience announced on the 11th that phase 2 clinical trial of CP-COV03 for COVID-19 patients has begun.
-
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
12/7/2021
CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19.
-
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal
5/24/2021
Hyundai Bioscience announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietary oral formulation technology, in a special issue of Pharmaceuticals.
-
An oral antiviral drug from Korea may be a problem solver for COVID-19
5/13/2021
New study indicating Niclosamide as 'COVID-19 game changer' was unveiled at Science Council of Asia Conference
-
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
4/19/2021
Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major shareholding bio tech company, CNPharm's single administration of 'Poly-COV01', which was developed as an injection for severely ill patients with the novel coronavirus infection (COVID- 19),
-
Hyundai Bioscience leads in the repurposing of Niclosamide
4/8/2021
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection, was published in the world-renowned SCI -level international journal and is attracting international attention.
-
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
12/22/2020
Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of COVID-19
-
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
12/8/2020
Hyundai Bioscience (KOSDAQ symbol: 048410) released a report on December 8 th that CP-COV03 , its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single administration. This pharmacokinetics study was recently p
-
Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide
10/29/2020
Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatment for COVID-19.
-
'Curing Cancer without Surgery'
6/30/2020
There has been an increase in the possibility for the 'conquering of cancer' as test results confirm, for the first time, the disappearance of tumors upon administering a 'pain-free anticancer drug.'
-
Hyundai Bioscience Unveils New Cancer Treatment that Offers Tumor Elimination without Painful Side Effects
7/9/2019
At the 2019 Global Bio Conference, the company released preliminary test results, achieving an 'almost full regression of pancreatic cancer' in animal testing
-
Acerus Reports Second Quarter 2018 Financial Results
8/13/2018
Acerus Pharmaceuticals Corporation reported its financial results for the three months and six months ended June 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.
-
Acerus Reports Fourth Quarter And Full Year 2016 Financial Results
3/8/2017